



(11) **EP 2 978 845 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72, 73

(51) Int Cl.:
C12N 15/113 ^(2010.01) **C07H 21/02** ^(2006.01)
A61K 31/713 ^(2006.01) **A61P 35/00** ^(2006.01)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(86) International application number:
PCT/EP2014/056221

(45) Date of publication and mention
of the grant of the patent:
29.04.2020 Bulletin 2020/18

(87) International publication number:
WO 2014/154835 (02.10.2014 Gazette 2014/40)

(21) Application number: **14713467.0**

(22) Date of filing: **27.03.2014**

(54) **MODIFIED TGF-BETA OLIGONUCLEOTIDES**
MODIFIZIERTE TGF-BETA-OLIGONUKLEOTIDE
OLIGONUCLÉOTIDES DE TGF-BETA MODIFIÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(74) Representative: **V.O.**
P.O. Box 87930
2508 DH Den Haag (NL)

(30) Priority: **27.03.2013 EP 13161474**
20.06.2013 EP 13173078
30.12.2013 EP 13199826

(56) References cited:
EP-A2- 1 008 649 EP-A2- 2 399 611
WO-A1-2011/154542 WO-A2-2005/084712

(43) Date of publication of application:
03.02.2016 Bulletin 2016/05

(73) Proprietor: **ISARNA Therapeutics GmbH**
80798 München (DE)

(72) Inventors:
• **JASCHINSKI, Frank**
82178 Puchheim (DE)
• **JANICOT, Michel**
1180 Brussels (BE)
• **UHLMANN, Eugen**
61479 Glashütten (DE)

- **STANTON ROBERT ET AL: "Chemical Modification Study of Antisense Gapmers", NUCLEIC ACID THERAPEUTICS, vol. 22, no. 5, October 2012 (2012-10), pages 344-359, XP055075730,**
- **MIHO TAKAGI-SATO ET AL: "Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression", NUCLEIC ACIDS SYMPOSIUM SERIES, no. 50, 2006, pages 319-320, XP003021650, ISSN: 0261-3166**
- **GORDON, K. & BLOBE, G.: "Role of transforming growth factor-beta superfamily signaling pathways in human disease.", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, vol. 1782, no. 4, 11 February 2008 (2008-02-11), pages 197-228, XP022540518, ISSN: 0925-4439 cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 978 845 B8